

Ephrata Community Hospital Antibiogram 2020 - Outpatient

Antibiogram represents organisms isolated from Jan to Dec 2020 and was prepared by members of the Departments of Microbiology and Pharmacy

| (%) Susceptibility Color Key: Green: ≥85% Yellow: 70-84% Red: <70% Based on CLSI recommendations only organisms with at least 30 isolates are reported. Susceptibility for additional organisms can be obtained from the Microbiology Department. | Gram Negative | | | | | Gram Positive | | | |
|---|------------------------------|------------------|-----------------------|-------------------|------------------------|-----------------------|--------------------------------------|--|-------------------------------|
| | Enterobacter cloacae complex | Escherichia coli | Klebsiella pneumoniae | Proteus mirabilis | Pseudomonas aeruginosa | Enterococcus faecalis | Staph. aureus, Methicillin RESISTANT | Staph. aureus, Methicillin SUSCEPTIBLE | Staph. sp. Coagulase Negative |
| Isolates | 33 | 964 | 130 | 56 | 74 | 113 | 44 | 89 | 47 |
| Amikacin | 100 | 99 | 100 | 100 | 98 | | | | |
| Amoxicillin/Clavulanate | | 88 | 96 | 94 | | | | 100 | 57 |
| Ampicillin | | 66 | | 83 | | 100 | | | |
| Ampicillin/Sulbactam | | 70 | 85 | 91 | | | | 100 | 57 |
| Azithromycin | | | | | | | | 56 | 50 |
| Aztreonam | 84 | 95 | 96 | 94 | 87 | | | | |
| Cefazolin | | 74 | 86 | 69 | | | | 100 | 57 |
| Cefepime | 96 | 96 | 96 | 94 | 97 | | | 100 | 57 |
| Ceftaroline | | | | | | | 100 | 100 | |
| Ceftazidime | 84 | 95 | 96 | 94 | 97 | | | | |
| Ceftazidime/Avibactam | | 99 | 100 | 100 | 97 | | | | |
| Ceftolozane/Tazobactam | | 99 | 99 | 100 | 98 | | | | |
| Ceftriaxone | 72 | 95 | 96 | 94 | | | | 100 | 57 |
| Cefuroxime | | 92 | 94 | 94 | | | | | |
| Ciprofloxacin | 100 | 88 | 95 | 83 | 91 | 76 | 29 | 84 | 61 |
| Clindamycin | | | | | | | 81 | 74 | 75 |
| Daptomycin | | | | | | 94 | 100 | 100 | 100 |
| Ertapenem | 87 | 100 | 100 | 100 | | | | | |
| Gentamicin | 100 | 95 | 96 | 94 | 86 | | | | |
| Imipenem | 81 | 99 | 100 | | 87 | | | 100 | 57 |
| Levofloxacin | 100 | 88 | 97 | 83 | 90 | 85 | 31 | 88 | 61 |
| Linezolid | | | | | | 98 | 100 | 100 | 100 |
| Meropenem | 100 | 100 | 100 | 100 | 97 | | | 100 | 75 |
| Nitrofurantoin | 30 | 98 | 41 | | | 100 | | 100 | 100 |
| Penicillin | | | | | | 100 | | | |
| Piperacillin/Tazobactam | 90 | 95 | 94 | 94 | 97 | | | 100 | 100 |
| Tetracycline | 96 | 82 | 86 | | | 31 | 88 | 96 | 87 |
| Tigecycline | 100 | 100 | 99 | | | | | | |
| Tobramycin | 100 | 95 | 96 | 96 | 97 | | | | |
| TMP/SMX | 90 | 84 | 91 | 82 | | | 100 | 100 | 82 |
| Vancomycin | | | | | | 100 | 100 | 100 | 100 |

* Antimicrobial susceptibility testing performed according to the guidelines set forth in: (1) Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests; approved standard-thirteenth addition. M2-A13, Vol. 38, No. 1. January 2018; (2) CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eleventh edition. M7-A11, Vol. 38, No. 2, January 2018; and (3) CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 30th edition Informational Supplement. M100-S29, January 2020.